Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fadraciclib by Cyclacel Pharmaceuticals for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
Fadraciclib by Cyclacel Pharmaceuticals for Cervical Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Plogosertib by Cyclacel Pharmaceuticals for Leukemia: Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Leukemia. According to GlobalData, Phase II...
Seliciclib by Cyclacel Pharmaceuticals for Rheumatoid Arthritis: Likelihood of Approval
Seliciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase...
Plogosertib by Cyclacel Pharmaceuticals for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to...
Fadraciclib by Cyclacel Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Plogosertib by Cyclacel Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Plogosertib by Cyclacel Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Plogosertib by Cyclacel Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Plogosertib by Cyclacel Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Plogosertib by Cyclacel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Laryngeal Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
Seliciclib by Cyclacel Pharmaceuticals for Rheumatoid Arthritis: Likelihood of Approval
Seliciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...